Midomafetamine
Phase 3Small molecule
Midomafetamine is a small molecule that works as a Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]
Midomafetamine is one of 57 small molecule programs targeting Central diabetes insipidus. It is currently in Phase 3.
3
Indications
23
Total Trials
2
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
63 competitors in Post-Traumatic Stress Disorder
#DrugCompanyPhaseTrials
1Minipress
PfizerApproved
Epidiolex
Jazz PharmaceuticalsApproved
Ritalin
NovartisApproved
Namenda
AbbVieApproved
Marinol
Jazz PharmaceuticalsApproved
Revia
TevaApproved
Zoloft
VViatris Specialty LLC
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment6 trials
Show 3 more trials
PTSD4 trials
Post-Traumatic Stress Disorder2 trials
Anxiety2 trials
7 more indications
Double-blind1 trial
Moderate Hepatic Impairment1 trial
Chronic PTSD1 trial
Relapse1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Midomafetamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Sodium-Dependent Dopamine Transporter Releasing Agent; Sodium-Dependent Noradrenaline Transporter Releasing Agent; Sodium-Dependent Serotonin Transporter Releasing Agent[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLykos Therapeutics